Induced-fit docking studies of the active and inactive states of protein tyrosine kinases

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 4, 2009, Pages 336-346

  Zhong, Haizhen ^a   Tran, Ly M ^a   Stang, Jenna L ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Erlotinib; Imatinib; Inhibitor design; Loop movement; Protein kinase

Indexed keywords

ERLOTINIB; IMATINIB; INHIBITOR DESIGN; LOOP MOVEMENT; PROTEIN KINASE;

AMINO ACIDS; BINDERS; BINDING ENERGY; DESIGN; DOCKING; LIGANDS;

TROPOSPHERE;

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ABELSON KINASE; BENZAMIDINE; CHALCONE DERIVATIVE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LIGAND; MOTESANIB; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; TANDUTINIB; VANDETANIB; VATALANIB;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MUTANT; PRIORITY JOURNAL;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; HYDROGEN BONDING; INDOLES; LIGANDS; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS;

ABELSON MURINE LEUKEMIA VIRUS;

EID: 70350574638     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2009.08.012     Document Type: Article

References (62)

1. Yarden Y., and Ullrich A. Growth factor receptor tyrosine kinase. Annu. Rev. Biochem. 57 (1988) 443-478
2. Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., von Pawel J., Thongprasert S., Tan E.H., Pemberton K., Archer V., and Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
3. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., Choi H.J., Kim Y.J., Shin S.J., Sohn J.H., Kim H., and Kim J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol. 25 (2007) 2528-2533
4. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
5. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
6. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D.M., and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
7. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
8. Weisberg E., Manley P., Breitenstein W., Bruggen J., Cowan-Jacob S., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., and Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
9. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., and Griffin J.D. AMN (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94 (2006) 1765-1769
10. Tokarski J.S., Newitt J., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., and Klei H.E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66 (2006) 5790-5797
11. Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P., Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D., and Manley P.W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukemia. Acta Crystallogr., Sect. D 63 (2007) 80-93
12. Atwell S., Adams J.M., Badger J., Buchanan M.D., Feil I.K., Froning K.J., Gao X., Hendle J., Keegan K., Leon B.C., Müller-Dieckmann H.J., Nienaber V.L., Noland B.W., Post K., Rajashankar K.R., Ramos A., Russell M., Burley S.K., and Buchanan S.G. A novel mode of Gleevec (STI-571 Imatinib) binding is revealed by the structure of spleen tyrosine kinase (Syk). J. Biol. Chem. 279 (2004) 55827-55832
13. Schrödinger, LLC: Portland, OR, 2007, Web address: www.schrodinger.com.
14. Kuntz I.D., Blaney J.M., Oatley S.J., Langridge R., and Ferrin T.E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161 (1982) 269-288
15. Rarey M., Kramer B., Lengauer T., and Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261 (1996) 470-489
16. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
17. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
18. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., and Shenkin P.S. Glide: a new approach for a rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004) 1739-1749
19. Carlson H.A. Protein flexibility and drug design: how to hit a moving target. Curr. Opin. Chem. Biol. 6 (2002) 447-452
20. Sherman W., Day T., Jacobson M.P., Friesner R.A., and Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
21. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., and Shewchuk L.M. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
22. Yun C.H., Boggon T.J., Li Y., Woo S., Greulich H., Meyerson M., and Eck M.J. Structures of lung cancer-derived egfr mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007) 217-227
23. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149
24. Ghosh K., Lau C.K., Guo F., Segall A.M., and van Duyne G.D. Peptide trapping of the Holliday junction intermediate in Cre-loxP site-specific recombination. J. Biol. Chem. 280 (2005) 8290-8299
25. MOE software, Chemical Computing Group Inc., Montreal, Canada, Web address: http://www.chemcomp.com.
26. Holm J., and Park J. DaliLite workbench for protein structure comparison. Bioinformatics 16 (2000) 566-567. http://www.ebi.ac.uk/Tools/dalilite/index.html World wide web address: http://www.ebi.ac.uk/Tools/dalilite/index.html
27. Zhong H., and Bowen J.P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr. Top. Med. Chem. 7 (2007) 1379-1393
28. T.A. Halgren, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94, J. Comp. Chem. 490-519.
29. Bowman A.L., Nikolovska-Coleska Z., Zhong H., Wang S., and Carlson H.A. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J. Am. Chem. Soc. 129 (2007) 12809-12814
30. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., and Mainz D.T. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49 (2006) 6177-6196
31. PYMOL, Delano Scientific LLC, San Carlos, CA, USA, Web address: http://pymol.sourceforge.net.
32. ClustalW server, the Swiss Institute of Bioinformatics, Basel, Switzerland, World Wide Web: http://www.ch.embnet.org/software/ClustalW.html.
33. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002) 46265-46272
34. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
35. Blencke S., Ullrichs A., and Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278 (2003) 15435-15440
36. Riley G.J., Politi K.A., Miller V.A., and Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12 (2006) 7232-7241
37. Hahn O., and Stadler W. Sofafenib. Curr. Opin. Oncol. 18 (2006) 615-621
38. Wilhelm S.M., and Chien D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 8 (2002) 2255-2257
39. Wilhelm S.M., Carter C., Tang L.Y., Wilkie D., McNabola A., Rong H., Chen C., Zhang X.M., Vincent P., McHugh M., Cao Y.C., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
40. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher D.C., George S., Bello C.L., Huang X., Baum C.M., and Casali P.G. Lancet 368 (2006) 1329-1338
41. Bold G., Altmann K.-H., Frei J., Lang M., Manley P.W., Traxler P., Wietfeld B., Brüggen J., Buchdunger E., Cozens R., Ferrari S., Furet P., Hofmann F., Martiny-Baron G., Mestan J., Rösel J., Sills M., Stover D., Acemoglu F., Boss E., Emmenegger R., Lässer L., Masso E., Roth R., Schlachter C., Vetterli W., Wyss D., and Wood J.M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 43 (2000) 2310-2323
42. Becker J.C., Mueller-Tidow C., Serve H., Domschke W., and Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J. Gastroenterol. 12 (2006) 3297-3305
43. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., Curwen J.O., Musgrove H.L., Graham G.A., Hughes G.D., Thomas A.P., Stokes E.S.E., Curry B., Richmond G.H.P., Wadsworth P.F., Bigley A.L., and Hennequin L.F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62 (2002) 4645-4655
44. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grossios K., Lane H.A., McSheehy P., Mestan J., Meyer T., Tang C., Wartmann M., Wood J., and Caravatti G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64 (2004) 4931-4941
45. B. Askew, J. Adams, S. Booker, G. Chen, L.V. Dipietro, D. Elbaum, J. Germain, S.D. Geuns-Meyer, G.J. Habgood, M. Handley, Q. Huang, T. Kim, A. Li, N. Nishimura, R. Nomak, V.F. Patel, B. Riahi, J.L. Kim, X. Ning, K. Yang, C.C. Yuan, Substituted alkylamine derivatives and methods of use, Amgen, Inc., U.S. patent 6,878,714 (2005).
46. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X.Y., Risau W., Ullrich A., Hirth K.P., and McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59 (1999) 99-106
47. Heymach J.V., Desai J., Manola J., Davis D.W., McConkey D.J., Harmon D., Ryan D.P., Goss G., Quigley T., Van den Abbeele A.D., Silverman S.G., Connors S., Folkman J., Fletcher C.D.M., and Demetri G.D. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 10 (2004) 5732-5740
48. Laird A.D., Christensen J.G., Li G.M., Carver J., Smith K., Xin X.H., Moss K.G., Louie S.G., Mendel D.B., and Cherrington J.M. SU6668 inhibits Flk-1/KDR and PDGFRß in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 16 (2002) 681-690
49. Smolich B.D., Yuen H.A., West K.A., Giles F.J., Albitar M., and Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97 (2001) 1413-1421
50. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N., Neuberg D., Scarborough R.M., Pandey A., Hollenbach S., Abe K., Lokker N.A., Gilliland D.G., and Giese N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 (2002) 421-432
51. Corbin A.S., Griswold I.J., Rosée P.L., Yee K.W.H., Heinrich M.C., Reimer C.L., Druker B.J., and Deininger M.W.N. Sensitivity of oncogenic KIT mutants to the kianse inhibtors MLN518 and PD180970. Blood 104 (2004) 3754-3757
52. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
53. Alberti M.J., Auten E.P., Lackey K.E., McDonald O.B., Wood E.R., Preugschat F., Cutler G.J., Kane-Carson L., Liu W., and Jung D.K. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1′,2′:1,5]pyrazolo[3,4-d]pyrimidines. Bioorg. Med. Chem. Lett. 15 (2005) 3778-3781
54. Nakamura H., Sasaki Y., Uno M., Yoshikawa T., Asano T., Ban H.S., Fukazawa H., Shibuya M., and Uehara Y. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinase. Bioorg. Med. Chem. Lett. 16 (2006) 5127-5131
55. Robinson T.P., Ehlers T., Hubbard R.B., Bai X., Arbiser J.L., Goldsmith D.J., and Bowen J.P. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg. Med. Chem. Lett. 13 (2003) 115-117
56. Robinson T.P., Hubbard IV R.B., Ehlers T.J., Arbiser J.L., Goldsmith D.J., and Bowen J.P. Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorg. Med. Chem. 13 (2005) 4007-4013
57. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G., Ladanyi M., Miller V.A., and Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12 (2006) 6494-6501
58. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7 (2007) 169-181
59. Kumar A., Petri E.T., Halmos B., and Boggon T.J. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26 (2008) 1742-1751
60. Zheng J., Trafny E.A., Knighton D.R., Xuong N.H., Taylor S.S., Ten Eyck L.F., and Sowadski J.M. 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr., Sect.D 49 (1993) 362-365
61. McGregor M.J. A pharmacophore map of small molecule protein kinase inhibitors. J. Chem. Inf. Model. 47 (2007) 2374-2382
62. May A., and Zacharias M. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking. J. Med. Chem. 51 (2008) 3499-3506